These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 18056004

  • 21. Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
    Kim H, Park JH, Lee JH, Lee JH, Joo YD, Lee WS, Bae SH, Mo Ryoo H, Lee KH, Cooperative Study Group A for Hematology.
    Am J Hematol; 2009 Mar; 84(3):161-6. PubMed ID: 19195034
    [Abstract] [Full Text] [Related]

  • 22. Enterocolitis as initial presentation of acute myelogenous leukemia exacerbated by induction chemotherapy with idarubicin-cytosine arabinoside.
    Wood RA.
    Mayo Clin Proc; 2002 Oct; 77(10):1133. PubMed ID: 12374257
    [No Abstract] [Full Text] [Related]

  • 23. [Intensive multi-drug chemotherapy for acute myeloid leukemia in a renal allograft recipient].
    Yamasaki J, Hata T, Fuchigami K, Togami K, Honda M, Fukushima T, Miyazaki Y, Jinnai I, Kuriyama K, Tomonaga M.
    Rinsho Ketsueki; 2003 Oct; 44(10):1015-9. PubMed ID: 14639948
    [Abstract] [Full Text] [Related]

  • 24. [Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].
    Kurahashi S, Iwasaki T, Suzuki H, Sawamoto A, Sugimoto T, Narimatsu H, Adachi T, Hayakawa F, Sugiura I.
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1617-21. PubMed ID: 17940376
    [Abstract] [Full Text] [Related]

  • 25. Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia--preliminary report.
    Łuczyński W, Muszyńska-Rosłan K, Krawczuk-Rybak M, Kuźmicz M, Iwaszkiewicz-Pawłowska A, Kaliszewski J.
    Med Sci Monit; 2001 Oct; 7(1):125-9. PubMed ID: 11208507
    [Abstract] [Full Text] [Related]

  • 26. A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
    Bradstock KF, Link E, Collins M, Di Iulio J, Lewis ID, Schwarer A, Enno A, Marlton P, Hahn U, Szer J, Cull G, Seymour JF, Australasian Leukaemia and Lymphoma Group.
    Br J Haematol; 2014 Dec; 167(5):618-25. PubMed ID: 25142189
    [Abstract] [Full Text] [Related]

  • 27. [Infection control in neutropenia induced by high-dose cytarabine chemotherapy].
    Miyazaki M, Senzaki K, Kiyoi H, Kohno S, Noda Y, Nabeshima T.
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2011-5. PubMed ID: 15570930
    [Abstract] [Full Text] [Related]

  • 28. Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
    Kawasaki Y, Kimura SI, Nakano H, Mashima K, Shirato Y, Kawaguchi SI, Toda Y, Ochi SI, Nagayama T, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Fujiwara SI, Ohmine K, Kako S, Muroi K, Kanda Y.
    Int J Hematol; 2019 Apr; 109(4):470-476. PubMed ID: 30684252
    [Abstract] [Full Text] [Related]

  • 29. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F.
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [Abstract] [Full Text] [Related]

  • 30. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 31. [Acute myelogenous leukemia complicated with severe tumor lysis syndrome after a single day of idarubicin/cytarabine chemotherapy].
    Kikuchi T, Miyata A, Fujii S, Kikuchi T.
    Rinsho Ketsueki; 2003 Nov; 44(11):1113-6. PubMed ID: 14689878
    [Abstract] [Full Text] [Related]

  • 32. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside.
    Hogan WJ, Letendre L, Litzow MR, Tefferi A, Hoagland HC, Pruthi RK, Kaufmann SH.
    Mayo Clin Proc; 2002 Aug; 77(8):760-2. PubMed ID: 12173711
    [Abstract] [Full Text] [Related]

  • 33. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
    Chen YJ, Zhang LQ, Li XL, Zhao XL, Wu DS, Shu YG, Chen FP.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
    [Abstract] [Full Text] [Related]

  • 34. [Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
    Obara Y, Nagai T, Mori M, Ohmine K, Toshima M, Komatsu N, Ozawa K.
    Rinsho Ketsueki; 2004 Oct; 45(10):1138-40. PubMed ID: 15553052
    [Abstract] [Full Text] [Related]

  • 35. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy.
    Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa J, Shimizu M, Oyama M, Moriwaki H.
    Hematol Oncol; 2008 Mar; 26(1):33-8. PubMed ID: 17918772
    [Abstract] [Full Text] [Related]

  • 36. Persistent hiccups as an adverse event to FLAG-IDA regimen for leukemia.
    Forghieri F, Maccaferri M, Morselli M, Potenza L, Volzone F, Bandieri E, Torelli G, Luppi M.
    Acta Oncol; 2009 Mar; 48(6):932-3. PubMed ID: 19235569
    [No Abstract] [Full Text] [Related]

  • 37. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.
    Cancer; 2008 Nov 01; 113(9):2504-11. PubMed ID: 18825661
    [Abstract] [Full Text] [Related]

  • 38. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
    Kalaycio M, Advani A, Pohlman B, Sekeres M, Tripp B, Rybicki L, Sobecks R.
    Am J Hematol; 2008 Nov 01; 83(11):831-4. PubMed ID: 18756545
    [Abstract] [Full Text] [Related]

  • 39. Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Zhang X, Guo X.
    Ann Hematol; 2019 Sep 01; 98(9):2223-2225. PubMed ID: 30980106
    [No Abstract] [Full Text] [Related]

  • 40. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
    Ferrara F, Mele G, Palmieri S, Pedata M, Copia C, Riccardi C, Izzo T, Criscuolo C, Musto P.
    Hematol Oncol; 2009 Dec 01; 27(4):198-202. PubMed ID: 19475701
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.